Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

(Reuters) -Kenvue beat quarterly profit and revenue estimates on Thursday as better-than-expected demand for cough-and-cold ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Gordon Haskett reports that the judge overseeing the initial California Tylenol lawsuit against Kenvue (KVUE) granted summary ...

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

We expect Kenvue, with the freedom to allocate capital and invest as a stand-alone entity, to focus on its 15 priority brands (including Tylenol, Nicorette, Listerine, and Zyrtec) to drive future ...

Kenvue beat Q1 sales estimates and updated its 2025 forecast as it manages foreign exchange impacts, tariffs, and leadership ...

Shares of Kenvue (KVUE) rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates. The former consumer ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the ...